局部晚期宫颈癌同步放化疗后辅助治疗研究进展

Research progress in adjuvant therapy after concurrent chemoradiotherapy for locally advanced cervical cancer

宫颈癌是女性生殖系统常见的恶性肿瘤,与高危型人乳头瘤病毒(HPV)持续感染密切相关。局部晚期宫颈癌(LACC)是指ⅠB3-ⅣA期(国际妇产科联盟2018分期)的宫颈癌,特征为肿瘤最长径大于4 cm或侵犯邻近组织。LACC的标准治疗是根治性放疗联合同步化疗,顺铂是首选的化疗药物。然而,局部晚期宫颈癌仍有进一步改善总体预后的临床需求,探索同步放化疗后有效的辅助治疗策略,提高LACC患者的治愈率和生活质量是临床实践中的重要课题。本文就LACC根治性放疗后辅助治疗的类型、适应证、效果及存在的问题进行综述。

Cervical cancer is a malignant tumor of the female reproductive system,which is closely related to persistent infection with high-risk human papillomavirus(HPV).Locally advanced cervical cancer(LACC)refers to cervical cancer of stage IB3 to IVA[International Federation of Gynecology and Obstetrics(FIGO)2018 staging],characterized by tumor diameter greater than 4 cm or invasion of adjacent tissues.The standard treatment for LACC is concurrent chemoradiotherapy,with cisplatin as the preferred chemotherapeutic agent.However,there is still a clinical need for further improvement of the overall prognosis of LACC,and exploring effective adjuvant treatment strategies after concurrent chemoradiotherapy to increase the cure rate and quality of life of LACC patients is an important topic in clinical practice.This article reviews the types,indications,effects and existing problems of adjuvant treatment after concurrent chemoradiotherapy for LACC.